Citations (29)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Kimberly M. Thompson, Dominika A. Kalkowska & Kamran Badizadegan. (2023) Oral polio vaccine stockpile modeling: insights from recent experience. Expert Review of Vaccines 22:1, pages 813-825.
Read now
Read now
Kimberly M. Thompson, Dominika A. Kalkowska & Kamran Badizadegan. (2021) Hypothetical emergence of poliovirus in 2020: part 2. exploration of the potential role of vaccines in control and eradication. Expert Review of Vaccines 20:4, pages 449-460.
Read now
Read now
Kimberly M. Thompson & Dominika A. Kalkowska. (2020) Review of poliovirus modeling performed from 2000 to 2019 to support global polio eradication. Expert Review of Vaccines 19:7, pages 661-686.
Read now
Read now
Kimberly M. Thompson & Dominika A. Kalkowska. (2019) Logistical challenges and assumptions for modeling the failure of global cessation of oral poliovirus vaccine (OPV). Expert Review of Vaccines 18:7, pages 725-736.
Read now
Read now
Radboud J. Duintjer Tebbens & Kimberly M. Thompson. (2018) Polio endgame risks and the possibility of restarting the use of oral poliovirus vaccine. Expert Review of Vaccines 17:8, pages 739-751.
Read now
Read now
Articles from other publishers (24)
Dominika A. Kalkowska, Steven G. F. Wassilak, Eric Wiesen, Cara C. Burns, Mark A. Pallansch, Kamran Badizadegan & Kimberly M. Thompson. (2023) Coordinated global cessation of oral poliovirus vaccine use: Options and potential consequences. Risk Analysis.
Crossref
Crossref
Dominika A. Kalkowska, Kamran Badizadegan & Kimberly M. Thompson. (2023) Outbreak management strategies for cocirculation of multiple poliovirus types. Vaccine 41:25, pages 3718-3727.
Crossref
Crossref
Dominika A. Kalkowska, Steven G.F. Wassilak, Mark A. Pallansch, Cara C. Burns, Eric Wiesen, Elias Durry, Kamran Badizadegan & Kimberly M. Thompson. (2023) Outbreak response strategies with type 2-containing oral poliovirus vaccines. Vaccine 41, pages A142-A152.
Crossref
Crossref
Dominika A. Kalkowska, Mark A. Pallansch, Steven G.F. Wassilak, Stephen L. Cochi & Kimberly M. Thompson. (2023) Serotype 2 oral poliovirus vaccine (OPV2) choices and the consequences of delaying outbreak response. Vaccine 41, pages A136-A141.
Crossref
Crossref
Dominika A. Kalkowska, Arend Voorman, Mark A. Pallansch, Steven G.F. Wassilak, Stephen L. Cochi, Kamran Badizadegan & Kimberly M. Thompson. (2023) The impact of disruptions caused by the COVID-19 pandemic on global polio eradication. Vaccine 41, pages A12-A18.
Crossref
Crossref
Kimberly M. Thompson, Dominika A. Kalkowska & Kamran Badizadegan. (2023) Looking back at prospective modeling of outbreak response strategies for managing global type 2 oral poliovirus vaccine (OPV2) cessation. Frontiers in Public Health 11.
Crossref
Crossref
Xinyue Chang, Xuelan Liu, Byron Martina, Andris Zeltins, Gilles Augusto, Monique Vogel, Mona O. Mohsen, Daniel E. Speiser & Martin F. Bachmann. (2023) Vaccination using mutated receptor binding domains of SARS-CoV-2: Evidence for partial immune escape but not serotype formation. Frontiers in Immunology 14.
Crossref
Crossref
Dominika A Kalkowska, Steven GF Wassilak, Eric Wiesen, Concepcion F Estivariz, Cara C Burns, Kamran Badizadegan & Kimberly M Thompson. (2023) Complexity of options related to restarting oral poliovirus vaccine (OPV) in national immunization programs after OPV cessation. Gates Open Research 7, pages 55.
Crossref
Crossref
Xinyue Chang, Xuelan Liu, Mona O. Mohsen, Andris Zeltins, Byron Martina, Monique Vogel & Martin F. Bachmann. (2022) Induction of Broadly Cross-Reactive Antibodies by Displaying Receptor Binding Domains of SARS-CoV-2 on Virus-like Particles. Vaccines 10:2, pages 307.
Crossref
Crossref
Arooj Nasir, Dumitru Baleanu, Ali Raza, Pervez Anwar, Nauman Ahmed, Muhammad Rafiq & Tahir Nawaz Cheema. (2022) Bio-Inspired Modelling of Disease Through Delayed Strategies. Computers, Materials & Continua 73:3, pages 5717-5734.
Crossref
Crossref
Muhammad Naveed, Dumitru Baleanu, Ali Raza, Muhammad Rafiq & Atif Hassan Soori. (2022) Treatment of Polio Delayed Epidemic Model via Computer Simulations. Computers, Materials & Continua 70:2, pages 3415-3431.
Crossref
Crossref
Konstantin Chumakov, Ellie Ehrenfeld, Vadim I Agol & Eckard Wimmer. (2021) Polio eradication at the crossroads. The Lancet Global Health 9:8, pages e1172-e1175.
Crossref
Crossref
Dominika A. Kalkowska, Mark A. Pallansch, Amanda Wilkinson, Ananda S. Bandyopadhyay, Jennifer L. Konopka‐Anstadt, Cara C. Burns, M. Steven Oberste, Steven G. F. Wassilak, Kamran Badizadegan & Kimberly M. Thompson. (2020) Updated Characterization of Outbreak Response Strategies for 2019–2029: Impacts of Using a Novel Type 2 Oral Poliovirus Vaccine Strain. Risk Analysis 41:2, pages 329-348.
Crossref
Crossref
Dominika A. Kalkowska & Kimberly M. Thompson. (2020) Expected Implications of Globally Coordinated Cessation of Serotype 3 Oral Poliovirus Vaccine (OPV) Before Serotype 1 OPV. Risk Analysis 41:2, pages 312-319.
Crossref
Crossref
Kimberly M. Thompson & Dominika A. Kalkowska. (2020) Potential Future Use, Costs, and Value of Poliovirus Vaccines. Risk Analysis 41:2, pages 349-363.
Crossref
Crossref
Dominika A. Kalkowska, Mark A. Pallansch, Stephen L. Cochi, Stephanie D. Kovacs, Steven G. F. Wassilak & Kimberly M. Thompson. (2020) Updated Characterization of Post‐OPV Cessation Risks: Lessons from 2019 Serotype 2 Outbreaks and Implications for the Probability of OPV Restart. Risk Analysis 41:2, pages 320-328.
Crossref
Crossref
Dominika A. Kalkowska, Richard Franka, Jeff Higgins, Stephanie D. Kovacs, Joseph C. Forbi, Steven G. F. Wassilak, Mark A. Pallansch & Kimberly M. Thompson. (2020) Modeling Poliovirus Transmission in Borno and Yobe, Northeast Nigeria. Risk Analysis 41:2, pages 289-302.
Crossref
Crossref
Kimberly M. Thompson & Dominika A. Kalkowska. (2020) Reflections on Modeling Poliovirus Transmission and the Polio Eradication Endgame. Risk Analysis 41:2, pages 229-247.
Crossref
Crossref
Dominika A. Kalkowska & Kimberly M. Thompson. (2020) Insights From Modeling Preventive Supplemental Immunization Activities as a Strategy to Eliminate Wild Poliovirus Transmission in Pakistan and Afghanistan. Risk Analysis 41:2, pages 266-272.
Crossref
Crossref
Kimberly M Thompson. (2019) Polio endgame options: will we have the vaccines needed?. The Lancet 394:10193, pages 99-100.
Crossref
Crossref
Radboud J. Duintjer Tebbens, Lee M. Hampton & Kimberly M. Thompson. (2018) Planning for globally coordinated cessation of bivalent oral poliovirus vaccine: risks of non-synchronous cessation and unauthorized oral poliovirus vaccine use. BMC Infectious Diseases 18:1.
Crossref
Crossref
Radboud J. Duintjer Tebbens, Mark A. Pallansch, Stephen L. Cochi, Derek T. Ehrhardt, Noha H. Farag, Stephen C. Hadler, Lee M. Hampton, Maureen Martinez, Steve G.F. Wassilak & Kimberly M. Thompson. (2018) Modeling Poliovirus Transmission in Pakistan and Afghanistan to Inform Vaccination Strategies in Undervaccinated Subpopulations. Risk Analysis 38:8, pages 1701-1717.
Crossref
Crossref
Radboud J. Duintjer Tebbens & Kimberly M. Thompson. (2018) Using integrated modeling to support the global eradication of vaccine-preventable diseases. System Dynamics Review 34:1-2, pages 78-120.
Crossref
Crossref
Ekaterina Korotkova, Majid Laassri, Tatiana Zagorodnyaya, Svetlana Petrovskaya, Elvira Rodionova, Elena Cherkasova, Anatoly Gmyl, Olga Ivanova, Tatyana Eremeeva, Galina Lipskaya, Vadim Agol & Konstantin Chumakov. (2017) Pressure for Pattern-Specific Intertypic Recombination between Sabin Polioviruses: Evolutionary Implications. Viruses 9:11, pages 353.
Crossref
Crossref